• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UCB expands in Brazil

UCB expands in Brazil

May 31, 2012
CenterWatch Staff

UCB, a global biopharmaceutical company focused on severe diseases, has signed an agreement to acquire 51% of Meizler Biopharma, a privately-owned Brazilian pharmaceutical company.

The agreement foresees performance related milestone payments in the coming years, as well as an option to purchase the remaining 49% of Meizler Biopharma later in time. The parties have agreed not to disclose further details pertaining to financial elements of the transaction.

"Our strategic partnership in Brazil with Meizler Biopharma is part of UCB’s growth strategy… [and] relies especially on their local infrastructure, Avi Meizler's and his team's experience and excellent reputation," said Roch Doliveux, CEO of UCB.

Doliveux continued, "Brazil is one of UCB’s key markets in which the company did not have a direct presence yet. It is currently the seventh largest biopharmaceutical market world-wide and is growing fast. With Meizler Biopharma, we look forward to building our presence in this region, creating a platform to launch UCB’s new products and making our medicines available to more patients.”

As part of the partnership, UCB will bring parts of its mature and new medicines into Meizler Biopharma's portfolio, which already covers central nervous system and immunology, for commercialization in Brazil. In 2011, the company had revenues in excess of $44 million. UCB will fully consolidate Meizler Biopharma financial results under the international accounting rules IFRS.

"We are very happy with our new partner UCB which strengthens Meizler Biopharma and brings the advantages of a global biopharmaceutical leader including a strong R&D pipeline of potential new products,” said Avi Meizler, founder, CEO and principle shareholder of Meizler Biopharma. “Knowledge and expertise sharing between our teams will create a platform for growth to the benefits of patients living with severe diseases."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing